Active Biotech Past Earnings Performance
Past criteria checks 0/6
Active Biotech's earnings have been declining at an average annual rate of -7.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 69.8% per year.
Key information
-7.7%
Earnings growth rate
7.6%
EPS growth rate
Biotechs Industry Growth | 0.7% |
Revenue growth rate | -69.8% |
Return on equity | -2,971.4% |
Net Margin | n/a |
Next Earnings Update | 13 Feb 2025 |
Recent past performance updates
Recent updates
Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation
Jun 05Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?
Feb 19Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely
Jul 27Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely
May 07Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation
Nov 09We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely
May 03We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate
Jan 18Revenue & Expenses Breakdown
How Active Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 0 | -42 | 13 | 29 |
30 Jun 24 | 0 | -44 | 13 | 31 |
31 Mar 24 | 0 | -45 | 14 | 32 |
31 Dec 23 | 0 | -46 | 14 | 33 |
30 Sep 23 | 0 | -48 | 16 | 33 |
30 Jun 23 | 0 | -51 | 16 | 36 |
31 Mar 23 | 0 | -54 | 15 | 39 |
31 Dec 22 | 0 | -58 | 15 | 43 |
30 Sep 22 | 0 | -60 | 15 | 44 |
30 Jun 22 | 0 | -57 | 15 | 41 |
31 Mar 22 | 0 | -56 | 16 | 40 |
31 Dec 21 | 0 | -50 | 15 | 35 |
30 Sep 21 | 6 | -38 | 14 | 30 |
30 Jun 21 | 6 | -35 | 13 | 28 |
31 Mar 21 | 6 | -32 | 13 | 25 |
31 Dec 20 | 7 | -32 | 13 | 26 |
30 Sep 20 | 1 | -39 | 13 | 27 |
30 Jun 20 | 2 | -40 | 13 | 27 |
31 Mar 20 | 3 | -36 | 13 | 26 |
31 Dec 19 | 8 | -34 | 12 | 28 |
30 Sep 19 | 12 | -32 | 11 | 29 |
30 Jun 19 | 16 | -31 | 11 | 33 |
31 Mar 19 | 21 | -35 | 10 | 38 |
31 Dec 18 | 20 | -37 | 11 | 39 |
30 Sep 18 | 21 | -88 | 11 | 40 |
30 Jun 18 | 21 | -88 | 11 | 40 |
31 Mar 18 | 20 | -103 | 19 | 45 |
31 Dec 17 | 20 | -109 | 20 | 49 |
30 Sep 17 | 22 | -63 | 21 | 56 |
30 Jun 17 | 21 | -67 | 22 | 58 |
31 Mar 17 | 20 | -59 | 16 | 58 |
31 Dec 16 | 19 | -60 | 16 | 58 |
30 Sep 16 | 17 | -86 | 16 | 71 |
30 Jun 16 | 18 | -97 | 17 | 82 |
31 Mar 16 | 17 | -152 | 17 | 128 |
31 Dec 15 | 16 | -194 | 18 | 176 |
30 Sep 15 | 14 | -210 | 17 | 202 |
30 Jun 15 | 12 | -243 | 17 | 233 |
31 Mar 15 | 11 | -229 | 18 | 220 |
31 Dec 14 | 10 | -232 | 17 | 222 |
30 Sep 14 | 12 | -257 | 18 | 247 |
30 Jun 14 | 116 | -171 | 18 | 268 |
31 Mar 14 | 116 | -194 | 17 | 290 |
31 Dec 13 | 116 | -212 | 17 | 308 |
Quality Earnings: ACTI is currently unprofitable.
Growing Profit Margin: ACTI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACTI is unprofitable, and losses have increased over the past 5 years at a rate of 7.7% per year.
Accelerating Growth: Unable to compare ACTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: ACTI has a negative Return on Equity (-2971.43%), as it is currently unprofitable.